| Literature DB >> 33594072 |
Jie Li1,2,3, Phillip M Galbo4, Weida Gong1, Aaron J Storey5, Yi-Hsuan Tsai1, Xufen Yu6, Jeong Hyun Ahn1,2, Yiran Guo1,3, Samuel G Mackintosh5, Ricky D Edmondson5, Stephanie D Byrum5, Jason E Farrar7, Shenghui He1,8, Ling Cai1,8, Jian Jin6, Alan J Tackett5,7, Deyou Zheng4,9, Gang Greg Wang10,11,12.
Abstract
Recurring chromosomal translocation t(10;17)(p15;q21) present in a subset of human acute myeloid leukemia (AML) patients creates an aberrant fusion gene termed ZMYND11-MBTD1 (ZM); however, its function remains undetermined. Here, we show that ZM confers primary murine hematopoietic stem/progenitor cells indefinite self-renewal capability ex vivo and causes AML in vivo. Genomics profilings reveal that ZM directly binds to and maintains high expression of pro-leukemic genes including Hoxa, Meis1, Myb, Myc and Sox4. Mechanistically, ZM recruits the NuA4/Tip60 histone acetyltransferase complex to cis-regulatory elements, sustaining an active chromatin state enriched in histone acetylation and devoid of repressive histone marks. Systematic mutagenesis of ZM demonstrates essential requirements of Tip60 interaction and an H3K36me3-binding PWWP (Pro-Trp-Trp-Pro) domain for oncogenesis. Inhibitor of histone acetylation-'reading' bromodomain proteins, which act downstream of ZM, is efficacious in treating ZM-induced AML. Collectively, this study demonstrates AML-causing effects of ZM, examines its gene-regulatory roles, and reports an attractive mechanism-guided therapeutic strategy.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33594072 PMCID: PMC7886901 DOI: 10.1038/s41467-021-21357-3
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919